171 related articles for article (PubMed ID: 34506104)
1. Development of a Benzothiazole Scaffold-Based Androgen Receptor N-Terminal Inhibitor for Treating Androgen-Responsive Prostate Cancer.
Kuznik NC; Solozobova V; Jung N; Gräßle S; Lei Q; Lewandowski EM; Munuganti R; Zoubeidi A; Chen Y; Bräse S; Cato ACB
ACS Chem Biol; 2021 Nov; 16(11):2103-2108. PubMed ID: 34506104
[TBL] [Abstract][Full Text] [Related]
2. BAG1L: a promising therapeutic target for androgen receptor-dependent prostate cancer.
Lee II; Kuznik NC; Rottenberg JT; Brown M; Cato ACB
J Mol Endocrinol; 2019 May; 62(4):R289-R299. PubMed ID: 30913537
[TBL] [Abstract][Full Text] [Related]
3. Dual androgen receptor (AR) and STAT3 inhibition by a compound targeting the AR amino-terminal domain.
Hua Y; Azeem W; Shen Y; Zhang S; Olsen JR; Øyan AM; Ke X; Zhang W; Kalland KH
Pharmacol Res Perspect; 2018 Dec; 6(6):e00437. PubMed ID: 30410767
[TBL] [Abstract][Full Text] [Related]
4. An androgen receptor N-terminal domain antagonist for treating prostate cancer.
Myung JK; Banuelos CA; Fernandez JG; Mawji NR; Wang J; Tien AH; Yang YC; Tavakoli I; Haile S; Watt K; McEwan IJ; Plymate S; Andersen RJ; Sadar MD
J Clin Invest; 2013 Jul; 123(7):2948-60. PubMed ID: 23722902
[TBL] [Abstract][Full Text] [Related]
5. Sintokamide A Is a Novel Antagonist of Androgen Receptor That Uniquely Binds Activation Function-1 in Its Amino-terminal Domain.
Banuelos CA; Tavakoli I; Tien AH; Caley DP; Mawji NR; Li Z; Wang J; Yang YC; Imamura Y; Yan L; Wen JG; Andersen RJ; Sadar MD
J Biol Chem; 2016 Oct; 291(42):22231-22243. PubMed ID: 27576691
[TBL] [Abstract][Full Text] [Related]
6. Discovery of drugs that directly target the intrinsically disordered region of the androgen receptor.
Sadar MD
Expert Opin Drug Discov; 2020 May; 15(5):551-560. PubMed ID: 32100577
[No Abstract] [Full Text] [Related]
7. Beyond androgen deprivation: ancillary integrative strategies for targeting the androgen receptor addiction of prostate cancer.
McCarty MF; Hejazi J; Rastmanesh R
Integr Cancer Ther; 2014 Sep; 13(5):386-95. PubMed ID: 24867960
[TBL] [Abstract][Full Text] [Related]
8. Combination therapy with androgen receptor N-terminal domain antagonist EPI-7170 and enzalutamide yields synergistic activity in AR-V7-positive prostate cancer.
Hirayama Y; Tam T; Jian K; Andersen RJ; Sadar MD
Mol Oncol; 2020 Oct; 14(10):2455-2470. PubMed ID: 32734688
[TBL] [Abstract][Full Text] [Related]
9. Lupeol, a novel androgen receptor inhibitor: implications in prostate cancer therapy.
Siddique HR; Mishra SK; Karnes RJ; Saleem M
Clin Cancer Res; 2011 Aug; 17(16):5379-91. PubMed ID: 21712449
[TBL] [Abstract][Full Text] [Related]
10. Targeting Binding Function-3 of the Androgen Receptor Blocks Its Co-Chaperone Interactions, Nuclear Translocation, and Activation.
Lallous N; Leblanc E; Munuganti RS; Hassona MD; Nakouzi NA; Awrey S; Morin H; Roshan-Moniri M; Singh K; Lawn S; Yamazaki T; Adomat HH; Andre C; Daugaard M; Young RN; Guns ES; Rennie PS; Cherkasov A
Mol Cancer Ther; 2016 Dec; 15(12):2936-2945. PubMed ID: 27765852
[TBL] [Abstract][Full Text] [Related]
11. Targeting the N-terminal domain of the androgen receptor: The effective approach in therapy of CRPC.
Ji Y; Zhang R; Han X; Zhou J
Eur J Med Chem; 2023 Feb; 247():115077. PubMed ID: 36587421
[TBL] [Abstract][Full Text] [Related]
12. Characterization of niphatenones that inhibit androgen receptor N-terminal domain.
Banuelos CA; Lal A; Tien AH; Shah N; Yang YC; Mawji NR; Meimetis LG; Park J; Kunzhong J; Andersen RJ; Sadar MD
PLoS One; 2014; 9(9):e107991. PubMed ID: 25268119
[TBL] [Abstract][Full Text] [Related]
13. Regression of castration-resistant prostate cancer by a novel compound QW07 targeting androgen receptor N-terminal domain.
Peng S; Wang J; Chen H; Hu P; He XL; He Y; Wang M; Tang W; He Q; Wang YY; Xie J; Guo D; Ren S; Liu M; Qiu WW; Yi Z
Cell Biol Toxicol; 2020 Oct; 36(5):399-416. PubMed ID: 32002708
[TBL] [Abstract][Full Text] [Related]
14. A sting in the tail: the N-terminal domain of the androgen receptor as a drug target.
Monaghan AE; McEwan IJ
Asian J Androl; 2016; 18(5):687-94. PubMed ID: 27212126
[TBL] [Abstract][Full Text] [Related]
15. Combined N-terminal androgen receptor and autophagy inhibition increases the antitumor effect in enzalutamide sensitive and enzalutamide resistant prostate cancer cells.
Kranzbühler B; Salemi S; Mortezavi A; Sulser T; Eberli D
Prostate; 2019 Feb; 79(2):206-214. PubMed ID: 30345525
[TBL] [Abstract][Full Text] [Related]
16. Small molecule inhibitors targeting the "achilles' heel" of androgen receptor activity.
Sadar MD
Cancer Res; 2011 Feb; 71(4):1208-13. PubMed ID: 21285252
[TBL] [Abstract][Full Text] [Related]
17. Identification of novel androgen receptor degrading agents to treat advanced prostate cancer.
Wu H; Ren J; Zhao L; Li Z; Ye W; Yang Y; Wang J; Bian J
Eur J Med Chem; 2021 May; 217():113376. PubMed ID: 33756125
[TBL] [Abstract][Full Text] [Related]
18. EPI-001 is a selective peroxisome proliferator-activated receptor-gamma modulator with inhibitory effects on androgen receptor expression and activity in prostate cancer.
Brand LJ; Olson ME; Ravindranathan P; Guo H; Kempema AM; Andrews TE; Chen X; Raj GV; Harki DA; Dehm SM
Oncotarget; 2015 Feb; 6(6):3811-24. PubMed ID: 25669987
[TBL] [Abstract][Full Text] [Related]
19. Novel selective agents for the degradation of AR/AR-V7 to treat advanced prostate cancer.
Yang Y; Lv G; Xiu R; Yang H; Wang W; Yu P; Zhang J; Ye L; Wang H; Tian J
Eur J Med Chem; 2024 May; 271():116400. PubMed ID: 38626524
[TBL] [Abstract][Full Text] [Related]
20. Peroxisome proliferator-activated receptor gamma coactivator-1alpha interacts with the androgen receptor (AR) and promotes prostate cancer cell growth by activating the AR.
Shiota M; Yokomizo A; Tada Y; Inokuchi J; Tatsugami K; Kuroiwa K; Uchiumi T; Fujimoto N; Seki N; Naito S
Mol Endocrinol; 2010 Jan; 24(1):114-27. PubMed ID: 19884383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
